Skip to main navigation
AADI Bioscience AADI Bioscience AADI Bioscience
Navigation
Primary Navigation
  • Company
    • The Company
    • Leadership
    • Board of Directors
  • Our Science
    • mTOR Pathway
    • TSC1 & TSC2
    • nab Technology Platform
    • Publications and Abstracts
  • Our Medicine
    • Our Medicine
    • Advanced Malignant PEComa
    • Expanded Access
  • Pipeline
  • Patients
    • Patient Advocacy
    • Clinical Trials
  • Investors & News
  • Contact Us
    • General Contact
    • For Healthcare Professionals
    • Careers

Press Release

Secondary Nav Investors & News
  • IR Overview
  • Stock
    • Stock Quote & Chart
    • Analyst Coverage
  • Press Releases
  • Event Calendar
  • Presentations
    • Corporate Presentations
    • Scientific Presentations
  • Financial
    • SEC Filings
    • Financial Reports
    • Quarterly Results
    • Forms
  • Governance
    • Governance Highlights
    • Committee Composition
  • IR Resources
    • Investor FAQ
    • Information Request
    • Email Alerts
    • IR Contacts

Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy

06/29/17
Phase 2b Study Aerpio Press Release_Final.pdf 379 KB

Toolkit

  • Print Page
  • RSS Feeds
  • Email Alerts
  • IR Contacts
logo

17383 Sunset Blvd, Suite A250
Pacific Palisades, CA 90272

Footer Links - Top
  • Home
  • Leadership
  • Pipeline
  • Patients
  • Contact
  • Careers
Footer Links - Bottom
  • LinkedIn
  • Twitter
  • Terms & Conditions
  • Privacy